Global /Taiwan /Healthcare /Biotechnology /1784

BIONET Corp.

1784

• TPEX: 1784 • Delayed

75.50TWD -0.3%

2.39 USD

As of 20 June 2026, BIONET Corp. has a market cap of $120.11M USD, ranking #24266 globally and #1266 in Taiwan. It ranks #2173 in the Healthcare sector, and #420 in the Biotechnology industry.

Global Rank

24266

Country Rank

1266

Sector Rank

2173

Industry Rank

420

Key Stats

Market Cap

$120.11MUSD

3.8B TWD

Enterprise Value

$110.51MUSD

3.5B TWD

Revenue (TTM)

$39.11MUSD

1.24B TWD

EBITDA (TTM)

$1.51MUSD

47.87M TWD

Net Income (TTM)

$1.63MUSD

51.43M TWD

EBITDA Margin

3.9%

Profit Margin

4.2%

PE Ratio

74.0

PS Ratio

3.1

PB Ratio

1.7

EV/EBITDA

73.0

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Qing Yuan Kang open_in_new

Founded

1989

Website

bionetcorp.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.3%	-3.6%	-4.8%	-23%	-16%	-27%	6.6%	29%	93%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	1784 訊聯生物科技股份有限公司 ISIN: TW0001784007 Shares Out.: Shares Outstanding: 50.306M¹ Shares Float: 43.47M² TV: TradingView: TPEX: 1784 SA: Stock Analysis: TPEX: 1784 YF: Yahoo Finance: 1784.TWO GF: Google Finance: TPEX: 1784 BA: Barron's: 1784 MS: Morningstar: ROCO: 1784	75.50 TWD	TV: TradingView: TPEX: 1784 SA: Stock Analysis: TPEX: 1784 YF: Yahoo Finance: 1784.TWO GF: Google Finance: TPEX: 1784 BA: Barron's: 1784 MS: Morningstar: ROCO: 1784

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About BIONET Corp.

BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived products; and Exosome, a cell-free therapy. The company was founded in 1989 and is based in Taipei City, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.46B 172.76B TWD 4K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 1K%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 796%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$726.25M 22.97B TWD 505%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$600.25M 18.98B TWD 400%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$571.26M 18.06B TWD 376%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 152K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 133K%	19.0	United States
argenx SE EBR: ARGX	$47.43B 41.39B EUR 39K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 37K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 35K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.88B 33.71B CHF 35K%	37.2	Switzerland

chevron_leftBack